Regina Berkovich1, Leslie P Weiner2. 1. MS Comprehensive Care Center at the University of Southern California Keck School of Medicine of USC, USA. Electronic address: rberkovi@usc.edu. 2. MS Comprehensive Care Center at the University of Southern California Keck School of Medicine of USC, USA.
Abstract
OBJECTIVE: To evaluate changes in absolute lymphocyte counts, lymphocyte subsets, and infections in patients treated with dimethyl fumarate (DMF) in comparison to the baseline pre-DMF levels. METHODS: A retrospective chart review was conducted of 23 MS patients treated with DMF. Absolute lymphocyte counts and lymphocyte subsets were obtained at baseline and after at least 3 months of DMF treatment. Data on infections requiring medical attention were also collected. RESULTS: A total of 23 patients were included in this analysis, 11 male (48%), 12 female (52%), with a mean age of 44.5±14.1 years, disease duration of 13.7±8.9 years, and EDSS of 3.5±1.7. The time between baseline and treatment lymphocyte counts was 3.9±1.2 months. Significant reductions in absolute lymphocyte counts by 35% (p<0.0001), CD3(+) by 34% (p<0.0001), CD4(+) by 34% (p<0.0001), CD8(+) by 40% (p<0.0001), and CD19(+) counts by 48% (p=0.0098) were found. Grade 2 lymphopenia occurred in 24% of patients and grade 3 lymphopenia occurred in 1 patient. Infections occurred in 26% of patients, mainly as urinary tract infections (22%) and one fatal case of West Nile encephalitis in a patient with grade 3 lymphopenia, who had been on DMF for 5 months. A detailed summary of this fatal case is provided. CONCLUSION: Lymphocyte subsets may help to provide better understanding of immunologic and safety impact of DMF.
OBJECTIVE: To evaluate changes in absolute lymphocyte counts, lymphocyte subsets, and infections in patients treated with dimethyl fumarate (DMF) in comparison to the baseline pre-DMF levels. METHODS: A retrospective chart review was conducted of 23 MSpatients treated with DMF. Absolute lymphocyte counts and lymphocyte subsets were obtained at baseline and after at least 3 months of DMF treatment. Data on infections requiring medical attention were also collected. RESULTS: A total of 23 patients were included in this analysis, 11 male (48%), 12 female (52%), with a mean age of 44.5±14.1 years, disease duration of 13.7±8.9 years, and EDSS of 3.5±1.7. The time between baseline and treatment lymphocyte counts was 3.9±1.2 months. Significant reductions in absolute lymphocyte counts by 35% (p<0.0001), CD3(+) by 34% (p<0.0001), CD4(+) by 34% (p<0.0001), CD8(+) by 40% (p<0.0001), and CD19(+) counts by 48% (p=0.0098) were found. Grade 2 lymphopenia occurred in 24% of patients and grade 3 lymphopenia occurred in 1 patient. Infections occurred in 26% of patients, mainly as urinary tract infections (22%) and one fatal case of West Nile encephalitis in a patient with grade 3 lymphopenia, who had been on DMF for 5 months. A detailed summary of this fatal case is provided. CONCLUSION: Lymphocyte subsets may help to provide better understanding of immunologic and safety impact of DMF.
Authors: Smathorn Thakolwiboon; Hannah Zhao-Fleming; Jie Pan; Jordan Knecht Scott; Eri Shoji; Gyeongmo Sohn; Mirla Avila Journal: Int J MS Care Date: 2020-05-18
Authors: Martin Diebold; Edoardo Galli; Andreas Kopf; Nicholas S R Sanderson; Ilaria Callegari; Pascal Benkert; Nicolás Gonzalo Núñez; Florian Ingelfinger; Stefan Herms; Sven Cichon; Ludwig Kappos; Jens Kuhle; Burkhard Becher; Manfred Claassen; Tobias Derfuss Journal: Proc Natl Acad Sci U S A Date: 2022-07-26 Impact factor: 12.779
Authors: Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Jonathan Izygon; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits Journal: Neurol Int Date: 2021-05-19
Authors: Steven K Lundy; Qi Wu; Qin Wang; Catherine A Dowling; Sophina H Taitano; Guangmei Mao; Yang Mao-Draayer Journal: Neurol Neuroimmunol Neuroinflamm Date: 2016-03-03
Authors: Rui Li; Ayman Rezk; Luke M Healy; Gillian Muirhead; Alexandre Prat; Jennifer L Gommerman; Amit Bar-Or Journal: Front Immunol Date: 2016-01-08 Impact factor: 7.561